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The acute airway narrowing that occurs as a result of exercise is defined exercise-induced bronchoconstriction (EIB).
Most recent guidelines recommend distinguishing EIB with underlying clinical asthma (EIBA) from the occurrence
of bronchial obstruction in subjects without other symptoms and signs of asthma (EIBwA). EIB has been in fact reported
in up to 90 % of asthmatic patients, reflecting the level of disease control, but it may develop even in subjects without
clinical asthma, particularly in children, athletes, patients with atopy or rhinitis and following respiratory infections.
Both EIBA and EIBwA have peculiar pathogenic mechanisms, diagnostic criteria and responses to treatment and
prevention. The use of biomarkers, proteomic approaches and innovative technological procedures will hopefully
contribute to better define peculiar phenotypes and to clarify the role of EIB as risk factor for the development of
asthma, as well as an occupational disease.
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Introduction
The term exercise-induced bronchoconstriction (EIB)
describes the acute airway narrowing that occurs as a re-
sult of exercise [1]. It has long been known that physical
exercise may trigger symptoms of asthma. However, the
interest for an objective study on this phenomenon may
be dated back to 50 years ago, when Jones and co-workers
focused on the physiologic response to exercise in asth-
matic children and named the airway obstruction after an
exercise challenge exercise-induced asthma (EIA) [2]. Sub-
sequent research defined the different patterns of response
to exercise in asthmatic patients, the effect of type, inten-
sity and duration of challenges, and the influence of anti-
asthmatic drugs on EIA.
In reviewing these studies, Godfrey concluded that,
despite of “some exceptions, there has been no evidence
that EIA occurs in patients other than asthmatics, and
although sporadic cases have been reported where exer-
cise appears to have been the only precipitant of asthma
in a patient (usually an adult), careful investigation has
usually revealed other clinical and physiological manifes-
tations of bronchial asthma” [3].* Correspondence: matteo.bonini@uniroma1.it
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unless otherwise stated.Although some authors consider EIA as a distinct asthma
phenotype [4], it is quite evident that exercise may trigger
bronchial obstruction and clinical symptoms in almost all
asthmatic patients, independently from the causes and
mechanisms of the underlying asthma. In fact, the preva-
lence of EIA has been reported in up to 90 % of asthmatic
patients, reflecting the level of disease control, with EIA
occurring more frequently in more severe and uncon-
trolled asthmatic patients [5].
However, the concept that exercise may induce bron-
chial obstruction in asthmatic patients only is in question
[6]. Exercise-induced bronchoconstriction (EIB) may in
fact develop even in subjects without clinical asthma. This
is particularly true in children, athletes, and patients with
atopy or rhinitis, or following respiratory infections [7-10].
It is not easy, however, to report prevalence rates in these
populations because they also depend on the type and in-
tensity of exercise, as well as the environmental conditions
in which the challenge is performed. Certainly, EIB that
occurs in athletes without clinical asthma has peculiar
clinical and pathologic features [11] and often disappears
after discontinuation of intense training [12].
To bring some clarity to this still controversial issue, a
Practice Parameter, jointly developed by the American
Academy/College of Allergy Asthma and Immunology
(AAAAI/ACAAI) [13], and more recently an Americanentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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mended to abandon the term of EIA (because exercise is
not the cause, but only a trigger of asthma) and to name
EIB with asthma (EIBA), the occurrence of bronchial
obstruction after exercise in asthmatic patients, and EIB
without asthma (EIBwA), the occurrence of bronchial ob-
struction in subjects without other symptoms and signs of
clinical asthma.
Pathogenesis
EIB was initially thought to be secondary to a mediator
release from mast cells [3]. This hypothesis was also sup-
ported by the refractory period observed after a positive
exercise challenge, interpreted as the time needed for mast
cell recharge, and by the preventive effect offered by mast
cell stabilizing agents, such as sodium cromoglycate. Al-
though mediator release does contribute to cause EIB,
pathophysiologic changes induced by intense exercising
are definitely more complex. At present, it is widely ac-
cepted that hyperventilation through the mouth associ-
ated with intense exercise causes the need for humidifying
and heating large volumes of air during a short period of
time. Elegant experiments performed by S.D. Anderson
and coworkers [15] show that the respiratory water loss
and the increase in osmolarity of the airways surface liquid
represent the major determinants of EIB (osmotic theory).
In fact, the dryer and cooler is the inspired air and the
higher is the ventilation, the greater is the likelihood of a
positive response to exercise, which also explains the
higher prevalence of EIB in winter sport disciplines [16].
The vasodilation associated with airways rewarming (ther-
mal theory) may also play a role in inducing bronchial ob-
struction after exercise [17].
In EIBA, the previously mentioned mechanisms only
represent a trigger of the underlying airway hyperreactiv-
ity in subjects with different phenotypes of asthma not
under control.
However, in EIBwA, the epithelial damage of a large
number of bronchial tree divisions down to peripheral
airways represents the predominant pathogenic mechan-
ism [18]. A direct effect of viral infections, occupational
agents and exercise may in fact represent a causal mech-
anism of bronchoconstriction, alternative to the classic
eosinophilic mast cell–dependent pathway occurring in
allergic asthma [19]. The role of epithelial damage and
of substances released by the epithelium and found in
sputum, such as interleukin-8 and leukotrienes [20, 21],
and in serum or urines, such as Nerve Growth Factor
(NGF) and the Clara cell protein CC16 [20, 22], may also
explain the heterogeneous inflammatory response re-
ported in EIBwA [23]. The increase of columnar epithelial
cells in induced sputum [20] is, in fact, associated with a
neutrophilic or mixed eosinophilic–neutrophilic inflam-
mation [24, 25]. The importance of aquaporin, expressedby the subepithelial glandular cells, in regulating the water
transport through the epithelium [26], as well as the in-
creased mucus production, as shown by the increased
expression of MUC5AC in induced sputum [27], may be
also relevant in EIBwA.
At last, autonomic dysregulation may also have a role in
causing bronchial obstruction in EIBwA [28], both through
the basal increased parasympathetic tone shown in ath-
letes and through reflex mechanisms induced by exercise.
Diagnosis
Research performed over the past twenty years in athletes
has consistently revealed a poor relationship between the
presence of ‘asthma-like’ symptoms and objective evi-
dence of EIB [29, 30]. Furthermore, pulmonary function
tests at baseline appear to be poorly predictive of EIB in
athletes, often being within the normal ranges even in
the presence of disease [31]. Thus, in order to establish
a secure diagnosis of EIB it is important to perform ob-
jective testing to confirm dynamic changes in airway
function [14].
Bronchoprovocative tests (BPTs)
After a careful history and physical examination, meas-
uring the change in the forced expiratory volume in the
1 s (FEV1) before and after a standardized exercise chal-
lenge test (ECT), in the laboratory or in the field, repre-
sents the most intuitive and commonly adopted approach
to diagnose EIB [32]. An ECT should be performed in
subjects with EIBA only when their baseline FEV1 is ≥70 %
of normal.
A ≥10 % fall in FEV1 at any two consecutive time-
point recordings (1, 3, 5, 10, 15, 20, 25, 30 min.) after 6
to 8 min of treadmill or cycloergometer exercise in am-
bient conditions (20-25 °C; relative humidity <50 %), is
considered diagnostic of EIB [32]. The intensity of exer-
cise should be enough to reach in the first 2–3 min. 40-
60 % of the predicted maximum voluntary ventilation
(estimated as baseline FEV1 X 35) or 80-90 % of the pre-
dicted maximal heart rate (calculated by 220 - age). In-
deed, it has been reported that the mean fall in FEV1
after an exercise challenge is more than doubled after
achieving 95 % of HR max, compared to 85 % [33].
Standard criteria for laboratory exercise testing may be
insufficient to induce a positive response in highly trained
individuals and may fail to properly reproduce the bronch-
oprovocative stimulus experienced by athletes practicing
their own sport discipline. Accordingly, sports-specific
challenges are also used in athletes. However, these are
more difficult to standardize, limiting their application.
Other BPTs may be adopted as surrogate diagnostic
tools for EIB. Direct BPTs, (i.e. methacholine and hista-
mine provocation), are accurate to document bronchial
hyperreactivity in asthma and in EIBA, while indirect
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saline challenge, and mannitol inhaled powder challenge,
better reproduce the effects of exercise on the airways
and are therefore more accurate to diagnose EIBwA [34].
Though, correlations between exercise tests and other
indirect BPTs are at present arguable and vary from test
to test [35].
The International Olympic Committee recommends
specific thresholds for the various BPTs to document
asthma or EIB and to permit the use of anti-asthmatic
drugs that are banned or limited by the World Anti-
Doping Agency (Table 1).
The differential diagnosis of EIB should take into ac-
count physiologic limitations; anxiety; exercise-induced
laryngeal dysfunctions, hyperventilation and hypox-
emia; dyspnoea on exertion in obese or poorly fit indi-
viduals; shortness of breath with exercise due to lung
diseases (other than asthma), cardiac diseases; anemia;
myopathies [14].
In particular, vocal cord dysfunction and structural
glottis abnormalities are increasingly recognized as con-
ditions that may mimic EIB [36]. However, in vocal cord
dysfunction, inspiratory stridor during exercise usually
resolves within 5 min representing the major differential
sign, associated with negative BPT result and poor re-
sponse to anti-asthmatic drugs. Vocal cord dysfunction
may also coexist with EIB.
If pruritus, urticaria or systemic reactions are associated
with symptoms of EIB, the diagnosis of exercise-induced
urticaria or anaphylaxis should be at last considered [37].
Treatment and Prevention
Treatment of both EIBA and EIBwA is essentially based
on reversing bronchial obstruction by using short-acting
beta-2 agonists [5].Table 1 International Olympic Committee criteria for the
diagnosis of asthma and permission to use of beta-2 agonists:
a positive clinical history associated to at least one positive test
is required
Diagnostic procedure Criteria
Pulmonary function FEV1 < 70 %, FEV1/VC <55 %
Bronchodilator test ↑ FEV1 ≥ 12 % or >200 ml
Eucapnic Voluntary Hyperpnea (EVH) ↓ FEV1 ≥ 10 %
Exercise challenge ↓ FEV1 ≥ 10 %
Methacholine challenge ↓ FEV1 ≥ 20 % with a:
PC20 ≤ 4 mg/ml (for subjects not
taking ICS)
or
PC20 ≤ 16 mg/ml (for subjects
taking ICS for at
least 1 month)
Hyperosmolar test (Mannitol, Saline) ↓ FEV1 ≥ 15 %Pharmacologic Prevention
Several pharmacologic approaches can be adopted to
prevent EIB [38]. Because EIBA is a sign of poor asthma
control, prevention essentially consists of following inter-
national guidelines to achieve asthma control [5]. The po-
tential occurrence of EIBA should not prevent asthmatic
patients from an adequate practice of physical exercise,
which is not associated to an increased risk of asthma de-
veloping or worsening and should instead represent part of
their treatment [39]. Multiple therapeutic options may be
also appropriate to prevent EIBwA, although usually they
do not completely avoid the occurrence of bronchocon-
striction, but rather attenuate it or shift the dose–response
relationship, so that some submaximal efforts become tol-
erated. Special precautions must be however taken with re-
spect to the World Anti-Doping Agency (WADA) rules on
the use of medications for EIBA and EIBwA in competitive
athletes (Table 2).
Mast cell stabilizers (not available in all countries), dis-
odium cromoglycate and nedocromil sodium, attenuate
both EIBA and EIBwA when inhaled shortly before exer-
cise, but only have a short duration of action [40].
Leukotriene antagonists (i.e. montelukast) have been
reported to be effective in preventing EIBA [41]. How-
ever, protection may not be complete and occurs in ap-
proximately 50 % of subjects [42].
Regular use of inhaled corticosteroid (ICS) represents
the therapy of choice for asthma control and therefore is
a recommended treatment to prevent EIBA [43]. The
prophylactic administration of ICS has been also sug-
gested in EIBwA, particularly if physical activity is per-
formed regularly (>3 times per week), representing a
repetitive stimulus for the onset of bronchoconstriction
[13]. However, the use of ICS in the prevention of EIBwA
may be controversial. In fact this pharmacological strategy
is at present not supported by ad-hoc designed clinical tri-
als and response to treatment may be impaired in subjects
with an underlying neutrophilic inflammatory pattern.
Beta-2 adrenergic drugs, both short- and long-acting
(SABA and LABA), when given in a single inhaled dose
or with intermittent administration before exercise, are
the most effective drugs to prevent both EIBA and EIBwA
[44], providing complete protection against exercise (FEV1
fall <10 %) in 68 % of subjects [45]. The effect usually lasts
2 to 4 h for SABA and up to 12 h for LABA. Heterogeneity
observed in the efficacy of beta-2 adrenergic agents to pre-
vent EIB is not dependent on the type of molecule used,
but rather on the population sample studied, with more
variable effects reported in children [46].
However, the chronic use of SABA and LABA often
results in a reduction of the duration and/or magnitude
of protection against EIB with cross-reacting tolerance
to other beta-2 agonists [45, 47]. This loss of efficacy seems
to be only partially prevented by ICS [48]. Furthermore,
Table 2 Most frequently used medications for EIBA and EIBwA and the 2015 World Anti-Doping Agency (WADA) regulations
Treatment WADA rules Notes




Systemic steroids Prohibited in competition
Beta-2 agonists Inhaled Salbutamol (max 1600 mcg/24H), Formoterol
(max 54 mcg/24H) and Salmeterol permitted
The presence in urine of salbutamol >1000 ng/mL or
formoterol >40 ng/mL is presumed not to be an
intended therapeutic use of the substance and will be
considered as an Adverse Analytical Finding




Immunotherapy Permitted SCIT should not be performed before or after physical exercise
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ing of EIB [49]. Therefore, SABA and LABA should be
used with caution on a daily basis to prevent EIB. At last,
LABA administration should be avoided without concomi-
tant use of ICS according to the U.S. Food and Drug Ad-
ministration (FDA) warning [50].
Ipratropium bromide prevents EIBA, although this effect
is not consistent among patients and may be variable in
the same patient [51]. Whether subjects with EIBwA or
with a prevalent autonomic imbalance represent an EIB
phenotype more responsive to anticholinergic agents rep-
resents an interesting hypothesis, still waiting for further
experimental testing [52].
Calcium channel blockers, beta-adrenergic receptor
antagonists, inhaled furosemide, heparin, and hyaluronic
acid have been studied to prevent EIB with inconsistent
results [13].
Non-Pharmacologic Prevention
Similar non-pharmacologic preventive measures can be
adopted in both EIBA and EIBwA [13]. These include,
whenever possible, avoiding exercise in an at-risk air en-
vironment because of temperature, humidity, and pollut-
ants or specific allergens in sensitized subjects. Gradual
warming-up and cooling-down periods are always sug-
gested. Some athletes also take advantage of the refractory
period after bronchial obstruction deliberately induced
by hyperventilation or by an intense exercise challenge.
The use of face masks which warm and humidify the
air has been reported to provide benefits. There is at
last some evidence that weight loss and dietary factors,
such as a low sodium intake, omega-3 polyunsaturated
fatty acids, or a supplementation of ascorbic acid may
be helpful in reducing the occurrence and severity of
EIB [53].Conclusions and Perspectives
Hyperventilation associated with exercise may induce
bronchial obstruction in asthmatic patients. However,
using the term EIA to define a specific asthma pheno-
type does not seem appropriate because exercise is only
a trigger of a symptom common to all etiologic forms of
asthma not under control. EIB may also occur in sub-
jects without clinical asthma. Both EIBA and EIBwA have
peculiar pathogenic mechanisms, diagnostic criteria and
responses to treatment and prevention. Further research
investigations are desirable to better understand rela-
tionships and differences between EIBA and EIBwA and
to definitely affirm if they represent two different pheno-
types. With this regards it is suggested to adopt a scientific
approach which includes the use of biomarkers, proteo-
mics and innovative technological procedures [54-57].
Moreover, it should be interesting to assess whether chil-
dren with EIBwA are at higher risk for developing clinical
asthma with age. At last, it should be questioned if EIB
in athletes should be considered an occupational disease
due to repeated exercising in inadequate environmental
conditions [58].
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